Garden State Investment Advisory Services LLC acquired a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 392,400 shares of the company's stock, valued at approximately $1,636,000. Garden State Investment Advisory Services LLC owned approximately 0.50% of MeiraGTx as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC grew its position in shares of MeiraGTx by 107.1% in the third quarter. Barclays PLC now owns 147,827 shares of the company's stock valued at $618,000 after purchasing an additional 76,437 shares in the last quarter. State Street Corp grew its holdings in MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company's stock valued at $2,397,000 after buying an additional 5,251 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in MeiraGTx during the third quarter worth about $2,795,000. Knoll Capital Management LLC acquired a new stake in shares of MeiraGTx during the 3rd quarter worth approximately $5,212,000. Finally, BNP Paribas Financial Markets increased its stake in MeiraGTx by 142.5% during the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company's stock worth $39,000 after acquiring an additional 5,476 shares during the last quarter. Hedge funds and other institutional investors own 67.48% of the company's stock.
MeiraGTx Trading Up 1.8 %
NASDAQ:MGTX traded up $0.11 on Friday, reaching $6.12. 210,986 shares of the company's stock were exchanged, compared to its average volume of 203,751. MeiraGTx Holdings plc has a 52-week low of $3.85 and a 52-week high of $7.60. The business has a fifty day moving average of $5.96 and a 200-day moving average of $4.93. The firm has a market capitalization of $478.30 million, a price-to-earnings ratio of -5.06 and a beta of 1.25. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Chardan Capital restated a "buy" rating and issued a $36.00 price objective on shares of MeiraGTx in a report on Monday, November 18th. Royal Bank of Canada upped their price target on MeiraGTx from $9.00 to $11.00 and gave the stock an "outperform" rating in a research note on Thursday, November 14th.
Read Our Latest Report on MeiraGTx
About MeiraGTx
(
Free Report)
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Read More
Before you consider MeiraGTx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.
While MeiraGTx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
